Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a virtual R&D Day on April 26, 2022 starting at 8:30 a.m. ET. Cyteir’s management will discuss the research done to identify the molecular target of CYT-0851 and review the ongoing clinical plan.
The live audio webcast can be accessed via the Investor Relations section of the Company’s website at www.cyteir.com . The archived webcast will remain available for replay on Cyteir’s website for 30 days.
About Cyteir Therapeutics, Inc.
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005211/en/
INVESTOR:
Lisa Hayes
Vice President, Investor Relations and Corporate Communications
908-868-8926
Lisa.Hayes@cyteir.com
MEDIA:
Michele Parisi
925-429-1850
mparisi@forwardhealthinc.com